The inaugural Fortune Innovation Forum was successfully held in Hong Kong from March 27 to 28, gathering experts, investors, and leaders from global enterprises to share unique insights on reshaping global economic forces. During the event, the highly anticipated Fortune “Future 30: Asia” list was officially unveiled. Imeik was named to the list, recognized for its strong R&D capabilities, robust product pipeline, and outstanding growth potential—establishing itself as a representative enterprise showcasing the vitality of development in the Asia-Pacific region.
Against the backdrop of escalating geopolitical tensions, ongoing energy crises, and mounting macroeconomic uncertainty, regions worldwide are actively exploring new pathways to overcome risks and challenges and foster sustainable economic growth. Since its inception in 1995, the Fortune conference has become one of the most influential global business gatherings, hosted in over 20 cities around the world. This year, the inaugural Fortune Innovation Forum focused on Asia—one of the most economically dynamic regions globally—and addressed critical issues such as the climate crisis and energy transition, global talent competition, financial sector reform, artificial intelligence, and digital transformation.
To stimulate long-term growth and innovation among enterprises and ensure Asia-Pacific remains competitive in the global business environment, Fortune, in partnership with the Boston Consulting Group (BCG Henderson Institute), launched the “Future 30: Asia” list. This list evaluates companies based on 19 factors across four core categories: strategy, technology and investment, talent, and financial structure. From over 700 Asia-Pacific companies with revenues or market capitalizations exceeding US$10 billion, 30 were selected for their innovation capacity and growth potential—comprising the top 20 most dynamic companies from China and 10 from the rest of Asia.
Previously, Fortune and BCG jointly developed the “Vitality Index” to quantify a company's long-term growth potential. This index is built on two pillars: a top-down market-based assessment of growth prospects, and a bottom-up analysis of a company's delivery capacity, covering aspects such as technology, structure, and strategic positioning.
Imeik (300896.SZ), one of the earliest companies in China to independently develop biomedical materials for medical aesthetics, enjoys high entry barriers and strong channel advantages. With a diverse and rare product portfolio, Imeik is well-positioned to meet evolving market demands. Backed by increasing industry standardization and self-regulation, the company’s marketed products and proprietary technologies showcase its core competitiveness in the medical aesthetics field.
Innovation is the cornerstone of long-term enterprise value. In recent years, Imeik has consistently ramped up R&D investment and expanded its strategic footprint across multiple sectors. Its rich pipeline spans medical devices, biopharmaceuticals, and chemical drugs, targeting applications such as anti-aging skincare, weight management, and post-operative recovery. Imeik is committed to developing integrated treatment solutions and strengthening its brand moat through diversified strategies and breakthrough innovations. Being selected as one of Fortune’s “Future 30: Asia” companies is a testament to its resilience, innovation capabilities, and forward-looking management in the face of uncertainty.
From a performance standpoint, Imeik has demonstrated steady growth. According to its recently released 2023 annual report, the company recorded RMB 2.869 billion in revenue and RMB 1.858 billion in net profit attributable to shareholders—both rising nearly 50% year-over-year. Net cash flow from operating activities reached RMB 1.954 billion, up 63.67% from the previous year.
As China emerges as the world’s second-largest medical aesthetics market, consumers are increasingly embracing aesthetic treatments as part of their daily lives. Everyone has the right to pursue beauty, and the minimally invasive aesthetics segment harbors tremendous vitality and growth potential.
Looking ahead, Imeik will continue to leverage its robust R&D capabilities, extensive product reserves, and sustainable strategic planning to maintain growth momentum, fuel innovation, and help drive the evolution of both the industry and regional economies.
